David R. Bauer

Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary shares of Oxford Immunotec Global PLC. The ordinary shares are…

Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5,296,053 shares of common stock of Spark Therapeutics, Inc. The…

Davis Polk advised Calyxt, Inc. in connection with its initial public offering of 8,050,000 shares of its common stock, including 1,050,000 shares of common stock sold pursuant to the full…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion registered offering by Eli Lilly and Company of $750 million principal amount of its 2.350% notes…

Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by Flexion Therapeutics, Inc. of $201.25 million aggregate principal amount of its 3.375% convertible…

Davis Polk is advising VF Corporation on the sale of its Licensed Sports Group business to Fanatics, Inc. The transaction, which is expected to close in the second quarter of 2017, is…

Davis Polk advised the representatives of the underwriters in connection with the $75.9 million offering of 3,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…